The success of tumor immunotherapy targeting the inhibitory co-receptors PD-1 and CTLA-4
has indicated that many other co-receptors might be potential druggable targets, despite …

T cell activation is tightly regulated by both stimulatory and inhibitory co-receptors and has
been a focus in the development of interventions for managing cancer or autoimmune …

Summary Lymphocyte activation gene-3 (LAG-3) is a potent inhibitory co-receptor; yet, its
functional ligand remains elusive, with distinct potential ligands identified. Here, we …

LAG3 is an inhibitory receptor that is highly expressed on exhausted T cells. Although LAG3-
targeting immunotherapeutics are currently in clinical trials, how LAG3 inhibits T cell function …

To prevent the destruction of tissues owing to excessive and/or inappropriate immune
responses, immune cells are under strict check by various regulatory mechanisms at …

Co-inhibitory receptors, such as CTLA-4 and PD-1, have an important role in regulating T
cell responses and have proven to be effective targets in the setting of chronic diseases …

Co-inhibitory receptors are important regulators of T-cell function that define the balance
between tolerance and autoimmunity. The immune regulatory function of co-inhibitory …

Inhibitory receptors on immune cells are pivotal regulators of immune escape in cancer.
Among these inhibitory receptors, CTLA-4 (targeted clinically by ipilimumab) serves as a …

The function mediated by the engagement of the lymphocyte activation gene-3 (LAG-3,
CD223) receptor expressed on activated T cells by its MHC class II ligand has remained …

Immunotherapy targeting coinhibitory receptors has been highly successful in treating a
wide variety of malignancies; however, only a subset of patients exhibits durable responses …